Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Hikma Pharmaceuticals ( (GB:HIK) ) just unveiled an update.
Hikma Pharmaceuticals disclosed that senior executives classified as Persons Discharging Managerial Responsibilities acquired additional ordinary shares through the company’s dividend reinvestment plan. The transactions, executed on 5 May 2026 on the London Stock Exchange at £14.098 per share, reflect automatic reinvestment of dividends into equity rather than cash payouts, modestly increasing management’s direct shareholdings.
The purchases by Hussein Arkhagha, Susan Ringdal and Julie Hill, totalling several thousand pounds, were reported in line with EU Market Abuse Regulation requirements as incorporated into U.K. law. While the scale of the acquisitions is limited, such participation in the reinvestment scheme may be seen by investors as a signal of ongoing alignment between senior management and shareholders through increased equity exposure.
The most recent analyst rating on (GB:HIK) stock is a Buy with a £1870.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.
Spark’s Take on HIK Stock
According to Spark, TipRanks’ AI Analyst, HIK is a Neutral.
The score is held back primarily by weakening cash generation and a notably bearish technical trend (oversold and trading below key moving averages). These are partially offset by attractive valuation (low P/E and strong dividend yield) and a constructive earnings-call outlook supported by guidance comfort and a GBP 250m buyback, despite near-term injectable headwinds.
To see Spark’s full report on HIK stock, click here.
More about Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC is a London-listed pharmaceutical company that develops, manufactures and markets a broad range of generic and branded medicines. The group focuses on injectables, generics and branded pharmaceutical products, with a strong presence across the Middle East and North Africa as well as key international markets.
Average Trading Volume: 1,372,426
Technical Sentiment Signal: Sell
Current Market Cap: £3.03B
For an in-depth examination of HIK stock, go to TipRanks’ Overview page.